Comparison of the Efficacy of SP-VATS Segmentectomy, SP-VATS Lobectomy, and 3P-VATS of Lobectomy in NSCLC Patients

Abstract

Abstract Objective: To analyze and study the clinical efficacy of single portal video-assisted thoracoscopic surgery (SP-VATS) segmentectomy, SP-VATS lobectomy, and conventional three portal video-assisted thoracoscopic surgery(3P-VATS) of lobectomy in the clinical treatment of non-small cell lung cancer （NSCLC) Method: Patients (n=180) with NSCLC treated in our hospital within two years (from June 2020 to June 2022) were randomly grouped (red, white and yellow bullets grouping) into groups A (conventional 3P-VATS of lobectomy, n= 60), B (SP-VATS segmentectomy, n= 60) and C (SP-VATS lobectomy, 60 cases). The clinical effects of three surgeries on NSCLC were compared and studied. Results: Compared with group A (conventional three-port thoracoscopic lobectomy), the levels of lung function-related indicators (FVC, FEV1, and MVV) were higher in groups B (SP-VATS segmentectomy) and C (SP-VATS lobectomy) (P<0.05); serum inflammation (IL-6, TNF-a, and CRP) and serum oxidative stress (Substance P and cortisol) were lower after treatment (P<0.05). The overall incidence of complications after surgery was lower (P<0.05), and the clinical efficacy was more significant (P<0.05). Conclusion: Compared with the clinical application of traditional 3P-VATS of lobectomy, SP-VATS segmentectomy, and SP-VATS lobectomy have significant efficacy in the clinical application which can improve the reduction of serum inflammation and serum oxidative stress-related index levels, which have more outstanding therapeutic advantages such as effectiveness and safety.